Skip to content
lifestyle.epubzone.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
ORIC Pharmaceuticals
ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer
July 14, 2026
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 2, 2026
ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates
May 4, 2026
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 1, 2026
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
February 11, 2026
←
Previous Page
1
2